title: Recent advances in management of the HIV/HCV coinfected patient.
abstract: Chronic hepatitis C virus (HCV) is a global epidemic, affecting approximately 150 million individuals throughout the world. The implications of HCV infection have been magnified in those who are infected with both HCV and the HIV as liver disease progression, liver failure and liver-related death are increased, particularly in those without well-controlled HIV disease. The development of direct-acting antiviral agents for HCV that allow shorter treatment periods with increased efficacy and decreased adverse events have greatly changed the outlook for HCV-infected individuals. With these advancements, growing treatment options for the coinfected population have also come. This review will address pharmacotherapy issues in the HIV/HCV coinfected population.
authors.affiliation: School of Pharmacy & Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA; New York State Center of Excellence in Bioinformatics & Life Sciences, University at Bufalo, 701 Ellicott Street, Buffalo, New York 14203, USA.
authors.forename: Cindy J
authors.initials: CJ
authors.lastname: Bednasz
authors.affiliation: School of Pharmacy & Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA.
authors.forename: Joshua R
authors.initials: JR
authors.lastname: Sawyer
authors.affiliation: Buffalo General Medical Center, University at Buffalo, Room. 617F, B Building, Buffalo, New York 14203, USA; Hepatology, Division of Gastroenterology, Hepatology & Nutrition, Erie County Medical Center, 462 Grider Street, Buffalo, New York 14215, USA.
authors.forename: Anthony
authors.initials: A
authors.lastname: Martinez
authors.affiliation: School of Pharmacy & Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA.
authors.forename: Patrick G
authors.initials: PG
authors.lastname: Rose
authors.affiliation: Translational Pharmacology Research Core, niversity at Buffalo, 701 Ellicott Street, Buffalo, New York 14203, USA.
authors.forename: Samantha S
authors.initials: SS
authors.lastname: Sithole
authors.affiliation: New York State Center of Excellence in Bioinformatics & Life Sciences, University at Bufalo, 701 Ellicott Street, Buffalo, New York 14203, USA; Immunodeficiency Services Clinic, Erie County Medical Center, 462 Grider Street, Buffalo, New York 14215, USA.
authors.forename: Holly R
authors.initials: HR
authors.lastname: Hamilton
authors.affiliation: Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, 701 Ellicott Street, Buffalo, New York 14203-1101, USA.
authors.forename: Farzia S
authors.initials: FS
authors.lastname: Kaufman
authors.affiliation: Center for Human Experimental Therapeutics, University of Rochester Medical Center, 265 Crittenden Blvd. CU 420694, Rochester, New York 14642-0694, USA.
authors.forename: Charles S
authors.initials: CS
authors.lastname: Venuto
authors.affiliation: School of Pharmacy & Pharmaceutical Sciences, New York State Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, 701 Ellicott Street, Buffalo, New York 14203, USA.
authors.forename: Qing
authors.initials: Q
authors.lastname: Ma
authors.affiliation: UBMD Center for Clinical Care & Research in Liver Disease, 875 Ellicott Street, Suite 6090, Buffalo, New York 14203, USA; Division of Gastroenterology, Hepatology and Nutrition, Clinical & Translational Research Center, 875 Ellicott Street, Suite 6090, Buffalo, New York 14203, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Talal
authors.affiliation: Pharmacy Practice (Medicine and Pediatrics), School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA; New York State Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, 701 Ellicott Street, Buffalo, New York 14203, USA.
authors.forename: Gene D
authors.initials: GD
authors.lastname: Morse
keywords: HCV; HIV; direct-acting antiviral; null responder; relapse; sustained virologic response